NO950950L - Farmasöytisk preparat - Google Patents

Farmasöytisk preparat

Info

Publication number
NO950950L
NO950950L NO950950A NO950950A NO950950L NO 950950 L NO950950 L NO 950950L NO 950950 A NO950950 A NO 950950A NO 950950 A NO950950 A NO 950950A NO 950950 L NO950950 L NO 950950L
Authority
NO
Norway
Prior art keywords
pharmaceutical preparation
diamorphine
admixture
diluent
hydrophobic
Prior art date
Application number
NO950950A
Other languages
English (en)
Other versions
NO950950D0 (no
Inventor
Ronald Brown Miller
Stewart Thomas Leslie
Derek Allan Prater
Trevor John Knott
Hassan Mohammad
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9404928A external-priority patent/GB2287880A/en
Priority claimed from GB9411842A external-priority patent/GB9411842D0/en
Priority claimed from EP94308493A external-priority patent/EP0654263B1/en
Priority claimed from GB9423498A external-priority patent/GB9423498D0/en
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of NO950950D0 publication Critical patent/NO950950D0/no
Publication of NO950950L publication Critical patent/NO950950L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Farmasøytisk preparat med regulert frigjøringsvirkning, spesielt for oral admi- nistrasjon, omfattende diamorfin eller et farmasøytisk akseptabelt salt derav, som aktiv bestanddel, fortrinnsvis i blanding med en hydrofob, smeltbar bærer eller fortynningsmiddel.
NO950950A 1994-03-14 1995-03-13 Farmasöytisk preparat NO950950L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9404928A GB2287880A (en) 1994-03-14 1994-03-14 Production of sustained release compositions
GB9411842A GB9411842D0 (en) 1994-06-14 1994-06-14 Pharmaceutical preparation
EP94308493A EP0654263B1 (en) 1993-11-23 1994-11-17 Method for preparing a sustained release composition
GB9423498A GB9423498D0 (en) 1994-11-21 1994-11-21 Pharmaceutical preparation

Publications (2)

Publication Number Publication Date
NO950950D0 NO950950D0 (no) 1995-03-13
NO950950L true NO950950L (no) 1995-09-15

Family

ID=27442925

Family Applications (1)

Application Number Title Priority Date Filing Date
NO950950A NO950950L (no) 1994-03-14 1995-03-13 Farmasöytisk preparat

Country Status (6)

Country Link
EP (1) EP0672416A1 (no)
JP (1) JPH0840905A (no)
AU (1) AU694475B2 (no)
CA (1) CA2144500A1 (no)
FI (1) FI951155L (no)
NO (1) NO950950L (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9519363D0 (en) * 1995-09-22 1995-11-22 Euro Celtique Sa Pharmaceutical formulation
GB9614902D0 (en) * 1996-07-16 1996-09-04 Rhodes John Sustained release composition
DE19729487A1 (de) * 1997-07-10 1999-01-14 Dresden Arzneimittel Verfahren zur Herstellung von Wirkstoff-Zubereitungen mit kontrollierter Freisetzung aus einer Matrix
CN1148171C (zh) * 1998-04-17 2004-05-05 大正制药株式会社 多单元缓释片剂
DE19923551A1 (de) * 1999-05-21 2000-11-30 Lohmann Therapie Syst Lts Pharmazeutisches Präparat mit dem Wirkstoff Diamorphin und seine Verwendung in einem Verfahren zur Behandlung der Opiatsucht
JP5189242B2 (ja) * 2002-09-23 2013-04-24 アルケルメス ファーマ アイルランド リミテッド 乱用抵抗性の医薬組成物
GB2403711A (en) * 2003-07-07 2005-01-12 Gw Pharma Ltd Drug dispenser with controlled access

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4132753A (en) * 1965-02-12 1979-01-02 American Cyanamid Company Process for preparing oral sustained release granules
GB8613688D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
SE9003296L (sv) * 1990-10-16 1992-04-17 Kabi Pharmacia Ab Foerfarande foer att formulera laekemedel
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
SE9200858L (sv) * 1992-03-20 1993-09-21 Kabi Pharmacia Ab Metod för framställning av pellets med fördröjd frisättning

Also Published As

Publication number Publication date
CA2144500A1 (en) 1995-09-15
AU1475595A (en) 1995-09-21
AU694475B2 (en) 1998-07-23
FI951155A7 (fi) 1995-09-15
JPH0840905A (ja) 1996-02-13
FI951155A0 (fi) 1995-03-13
EP0672416A1 (en) 1995-09-20
FI951155L (fi) 1995-09-15
NO950950D0 (no) 1995-03-13

Similar Documents

Publication Publication Date Title
CA2123160A1 (en) Controlled release formulation
EP0348808A3 (de) Neue Arzneimittelformulierung sowie Verfahren zu deren Herstellung
EE200000329A (et) Oraalne manustamisvorm happes ebapüsivate toimeainete tarbeks, selle valmistamismeetod ja happes ebapüsivat toimeainet sisaldava toimeaineühiku kasutamine
UY26372A1 (es) "imidazo-3-il-aminas bicíclicas procedimiento para su preparación y medicamentos que las contienen "
MY100721A (en) Therapeutic agent.
NO953874L (no) Farmasöytisk preparat inneholdende lipofile legemidler
ITRM920155A1 (it) Composizione farmaceutica contenente 3-2 (dimetilammino) etil-n-metil1h-indol-5-metansolfonammide, relativo procedimento di preparazione e impiego della stessa nel trattamento di mammiferi
NO308538B1 (no) Imidazo (4,5-c) kinolinaminer
WO1999055332A8 (en) Medicinal compositions
DK1121127T3 (da) Orale farmaceutiske sammensætninger, som indeholder buprenorphin
NO20013060L (no) Kontrollert frigjörende farmasöytisk preparat med tilidinmesylat som virkestoff
CA2304135A1 (en) Medicament formulation with a controlled release of an active agent
AU1277792A (en) Compositions for topical administration containing fluticasone propionate and oxiconazole or its salts
ES2062137T3 (es) Utilizacion de 5'-deoxi-5'-metil-tioadenosina, s-adenosilmetionina y sus sales para la preparacion de composiciones farmaceuticas reductoras de seborrea.
AU3318389A (en) Azelastine-containing medicaments with controlled release of the active substance
DE69915487D1 (de) Erythromycin-derivate mit antibiotischer wirkung
HUT50334A (en) Process for producing arylpiperazinyl-alkilenephenyl-p-heterocycluc compounds, pharmaceutically acceptable acid addition salts thereof and pharmaceutical compositions comprising the compounds as active ingredient
GR890100833A (en) Process for the preparation of a compound with gastric inhibitopy effect
EE9400296A (et) Piperidinüültioindooli derivaadid, ravimvormid, aktiivne valuvaigisti, nende valmistamise meetodid
HRP20050342B1 (hr) Farmaceutska formulacija olanzapina
AU1146688A (en) Agent having renal function-improving effect and diuretic effect
IT8621097A0 (it) Composizioni farmaceutiche. derivato di timo attivo per via orale, procedimenti per la sua preparazione e relative
IE840977L (en) Pharmaceutical preparations
EP0351876A3 (en) Composition for potentiating vaccination effect
DE59205998D1 (de) Arzneimittel mit antineoplastischer Wirkung enthaltend als Wirkstoff Octadecyl-[2-(N-methylpiperidino)-ethyl]-phosphat und Verfahren zu dessen Herstellung